Ezzat, A.A.; Tammam, S.N.; Weiskirchen, R.; Schröder-Lange, S.K.; Mansour, S.
Targeted Liver Fibrosis Therapy: Evaluating Retinol-Modified Nanoparticles and Atorvastatin/JQ1-Loaded Nanoparticles for Deactivation of Activated Hepatic Stellate Cells. Livers 2025, 5, 63.
https://doi.org/10.3390/livers5040063
AMA Style
Ezzat AA, Tammam SN, Weiskirchen R, Schröder-Lange SK, Mansour S.
Targeted Liver Fibrosis Therapy: Evaluating Retinol-Modified Nanoparticles and Atorvastatin/JQ1-Loaded Nanoparticles for Deactivation of Activated Hepatic Stellate Cells. Livers. 2025; 5(4):63.
https://doi.org/10.3390/livers5040063
Chicago/Turabian Style
Ezzat, Aya A., Salma N. Tammam, Ralf Weiskirchen, Sarah K. Schröder-Lange, and Samar Mansour.
2025. "Targeted Liver Fibrosis Therapy: Evaluating Retinol-Modified Nanoparticles and Atorvastatin/JQ1-Loaded Nanoparticles for Deactivation of Activated Hepatic Stellate Cells" Livers 5, no. 4: 63.
https://doi.org/10.3390/livers5040063
APA Style
Ezzat, A. A., Tammam, S. N., Weiskirchen, R., Schröder-Lange, S. K., & Mansour, S.
(2025). Targeted Liver Fibrosis Therapy: Evaluating Retinol-Modified Nanoparticles and Atorvastatin/JQ1-Loaded Nanoparticles for Deactivation of Activated Hepatic Stellate Cells. Livers, 5(4), 63.
https://doi.org/10.3390/livers5040063
